CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Singapore

GlobalData, the industry analysis specialist, has released its latest report: “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Singapore”. The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Singapore. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

Singapore’s population grew from 5 million in 2009 to 5.6 million in 2016, mainly due to the increase in the life expectancy. The value of the pharmaceuticals market increased from $645m in 2009 to $903m in 2016 at a Compound Annual Growth Rate (CAGR) of 5%, and this value is expected to increase further from $947m in 2017 to $1,148m in 2021 at a CAGR of 5%. In 2015, the medical device market size of Singapore was $1.69 billion.

These positive growth trends can be primarily attributed to:

  • An increasingly elderly population
  • Universal health coverage
  • Government initiatives

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Singapore, and includes:

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Merck & Co., Sanofi, Hyphens Pharma, Novartis, and Valeant.
  • An insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
  • Detailed analysis of the country’s political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Singaporean healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to:

  • Develop business strategies by understanding the trends shaping and driving Singapore’s healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Singapore’s healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

3 Introduction

3.1 GlobalData Report Guidance

4 ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

3 Introduction

3.1 GlobalData Report Guidance

4 Overview of Pharmaceutical and Medical Device Markets

4.1 Pharmaceutical Market

4.1.1 Market Overview

4.1.2 Pharmaceutical Exports and Imports

4.1.3 Supply Channels

4.1.4 Market Segments

4.1.5 Overview of Major Disease Areas

4.1.6 Major Players

4.2 Medical Device Market

4.2.1 Market Overview

4.3 Market Drivers and Barriers

4.3.1 Drivers

4.3.2 Barriers

5 Market Access

5.1 Overview of Healthcare System

5.1.1 Reimbursement Process

5.1.2 Overview of Insurance Providers

5.1.3 Patient Share in Healthcare Expenditure

5.1.4 Price Trends in the Healthcare Sector

5.1.5 Pricing Policies

5.2 Regulatory Landscape

5.2.1 Overview of Regulatory Agencies

5.2.2 Market Authorization Procedure for Pharmaceutical Products

5.2.3 New Medical Device Approval Process

5.2.4 Licensing Process for Pharmaceutical and Medical Device Manufacturing

5.2.5 Exports and Imports

5.2.6 Intellectual Property Rights

5.2.7 Clinical Trial Regulations

5.2.8 Pharmaceutical Advertising Regulations

5.2.9 Pharmacy Regulations

5.2.10 Labeling and Packaging Regulations

6 Country Analysis

6.1 Political Environment

6.1.1 Current Political Environment

6.1.2 Healthcare Policy Initiatives

6.2 Economic Landscape

6.3 Economic Indicators

6.3.1 Gross Domestic Product

6.3.2 Gross National Income

6.3.3 Inflation

6.3.4 Currency Exchange Rate

6.3.5 Foreign Direct Investment

6.3.6 Foreign Exchange Reserves

6.3.7 Trade Balance

6.3.8 Government Structural Balance

6.3.9 Government Net Debt

6.3.10 Major Industries

6.4 Demographics

6.4.1 Population

6.4.2 Education and Literacy

6.4.3 Employment

6.4.4 Disease Burden

6.5 Healthcare Infrastructure

6.5.1 Healthcare Facilities

6.5.2 Healthcare Parameters

6.5.3 Environmental Health

6.5.4 Healthcare Personnel

6.6 Healthcare Expenditure

6.6.1 Overview

6.6.2 Share of Public and Private Sectors

6.6.3 Major Components of Healthcare Expenditure

6.6.4 Spending in Pharmaceutical R&D

6.7 Trade Associations

6.7.1 The Singapore Association of Pharmaceutical Industries

6.7.2 The Singapore Medical Association

6.7.3 The Society for Emergency Medicine in Singapore

6.7.4 The Pharmaceutical Society of Singapore

6.7.5 The Healthcare Quality Society of Singapore

6.8 Trade Fairs

7 Opportunities and Challenges

7.1 Opportunities

7.2 Challenges

8 Appendix

8.1 Abbreviations

8.2 Bibliography

8.3 Research Methodology

8.3.1 Coverage

8.3.2 Secondary Research

8.3.3 Forecasts

8.3.4 Expert Panel

8.4 Contact Us

8.5 Disclaimer

List of Tables

Table 1: Pharmaceutical Market, Singapore, Revenue ($m), 2009–2016

Table 2: Pharmaceutical Market, Singapore, Revenue ($m), 2017–2021

Table 3: Pharmaceutical Market, Singapore, Exports and ...

Table 1: Pharmaceutical Market, Singapore, Revenue ($m), 2009–2016

Table 2: Pharmaceutical Market, Singapore, Revenue ($m), 2017–2021

Table 3: Pharmaceutical Market, Singapore, Exports and Imports ($bn), 2009–2016

Table 4: Pharmaceutical Market, Merck & Co., Global, Major Products, 2017

Table 5: Pharmaceutical Market, Merck & Co., Global, Late-Stage Pipeline, 2017

Table 6: Major Products, Sanofi, Global, 2017

Table 7: Late-Stage Pipeline, Sanofi, Global, 2015

Table 8: Major Products, Novartis, Global, 2017

Table 9: Late-Stage Pipeline, Novartis, Global, 2017

Table 10: Pharmaceutical Market, Valeant, Global, Major Products, 2017

Table 11: Pharmaceutical Market, Valeant, Global, Late-Stage Pipeline, 2017

Table 12: Market Access, Singapore, MediSave Wage Contribution (%), 2014

Table 13: Market Access, Singapore, MediShield Premium Payment Scheme by Age Group ($), 2015

Table 14: Market Access, Singapore, Medisave-Approved Integrated Shield Plans Withdrawal Limit by Age Group ($), 2014

Table 15: Market Access, Singapore, Additional Withdrawal Limit by Age Group ($), 2015

Table 16: Healthcare Expenditure, Singapore, Out-of-Pocket Expenditure (%), 2009–2016

Table 17: Market Access, Singapore, Healthcare Consumer Price Index Annual Change (%), 2009–2015

Table 18: Market Access, Singapore, RegistrationDossier Format, 2016

Table 19: Market Access, Singapore, Registration Dossier Format, 2016

Table 20: Market Access, Singapore, Registration Dossier Format, 2016

Table 21: Market Access, Singapore, GMP Certificate Fees for Medicinal Products and Active Pharmaceutical Ingredients ($), 2016

Table 22: Market Access, Singapore, Manufacturer’s License Fees for Medicinal Products ($), 2016

Table 23: Market Access, Singapore, Manufacturer’s License Fees for Medicinal Products ($), 2016

Table 24: Market Access, Singapore, Wholesale Dealer’s License Fees for Medicinal Products ($), 2016

Table 25: Market Access, Singapore, Patent Co-operation Treaty, International Application Process, 2014

Table 26: Market Access, Singapore, Patent Filing Fees and Charges, 2017

Table 27: Market Access, Singapore, Clinical Trial Certificates Issued, 2009–2015

Table 28: Market Access, Singapore, Clinical Trials by Therapeutic Area (%), 2015

Table 29: Market Access, Singapore, Target Processing Timelines of Clinical Trial, 2016

Table 30: Market Access, Singapore, Fees for Advertisement Permit ($), 2016

Table 31: Market Access, Singapore, Labeling Requirements, 2014

Table 32: Economic Indicators, Singapore, GDP per Capita ($), 2009–2016

Table 33: Economic Indicators, Singapore, GDP per Capita ($), 2017–2021

Table 34: Economic Indicators, Singapore, GDP Annual Growth (%), 2009–2016

Table 35: Economic Indicators, Singapore, GDP Annual Growth (%), 2017–2021

Table 36: Economic Indicators, Singapore, GNI per Capita ($), 2009–2016

Table 37: Economic Indicators, Singapore, Consumer Price Index, 2009–2016

Table 38: Economic Indicators, Singapore, Average Consumer Price Index, 2017–2021

Table 39: Economic Indicators, Singapore, Average Consumer Price Index Annual Change (%), 2009–2016

Table 40: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), 2017–2021

Table 41: Economic Indicators, Singapore, Currency Exchange Rate (SGD/$), 2009–2016

Table 42: Economic Indicators, Singapore, Foreign Direct Investment ($bn), 2009–2016

Table 43: Economic Indicators, Singapore, Foreign Exchange Reserves ($bn), 2009–2016

Table 44: Economic Indicators, Singapore, Imports of Goods and Services ($bn), 2009–2016

Table 45: Economic Indicators, Singapore, Exports of Goods and Services ($bn), 2009–2016

Table 46: Economic Indicators, Singapore, General Government Structural Balance ($bn), 2009–2016

Table 47: Economic Indicators, Singapore, Government Net Debt as a Percentage of GDP (%), 2009–2016

Table 48: Economic Indicators, Singapore, Government Net Debt as a Percentage of GDP (%), 2017–2021

Table 49: Economic Indicators, Singapore, Value Added by Major Industries ($bn), 2015

Table 50: Demographics, Singapore, Population (million), 2009–2016

Table 51: Demographics, Singapore, Population (million), 2017–2021

Table 52: Demographics, Singapore, Urban–Rural Population Share (%), 2009–2016

Table 53: Demographics, Singapore, Urban–Rural Population Share (%), 2017–2021

Table 54: Demographics, Singapore, Population Distribution by Age Group (%), 2009–2016

Table 55: Demographics, Singapore, Population Distribution by Age Group (%), 2017–2021

Table 56: Demographics, Singapore, Births (per 1,000 Population), 2009–2016

Table 57: Demographics, Singapore, Mortality (per 1,000 Population), 2009–2016

Table 58: Demographics, Singapore, Major Causes of Mortality (%), 2015

Table 59: Demographics, Singapore, Mortality Rate of Children Under Five (per 1,000 live births), 2009–2016

Table 60: Demographics, Singapore, Immunization Rate (%), 2009–2016

Table 61: Demographics, Singapore, Major Causes of Male Mortality (‘000), 2015

Table 62: Demographics, Singapore, Major Causes of Female Mortality (‘000), 2015

Table 63: Demographics, Singapore, Gender Ratio (M/F), 2009–2016

Table 64: Demographics, Singapore, Life Expectancy at Birth (years), 2009–2016

Table 65: Demographics, Singapore, Life Expectancy at Birth (years), 2017–2021

Table 66: Demographics, Singapore, Student Enrollment by Level of Education (%), 2015

Table 67: Demographics, Singapore, Unemployment Rate (%), 2009–2016

Table 68: Demographics, Singapore, Disability-Adjusted Life Years by Major Disease (‘000), 2015

Table 69: Healthcare Infrastructure, Singapore, Hospitals, 2009–2016

Table 70: Healthcare Infrastructure, Singapore, Public and Private Hospitals, 2009–2016

Table 71: Healthcare Infrastructure, Singapore, Hospitals Beds by Sector, 2009–2016

Table 72: Healthcare Infrastructure, Singapore, Hospitals Beds (per 1,000 population), 2009–2016

Table 73: Healthcare Infrastructure, Singapore, Doctors (per 1,000 population), 2009–2016

Table 74: Healthcare Infrastructure, Singapore, PM2.5 (µg per m³), 2009–2016

Table 75: Healthcare Infrastructure, Singapore, CO2 Emissions (metric tons per capita), 2009–2016

Table 76: Healthcare Infrastructure, Singapore, Nurses (per 1,000 population), 2009–2016

Table 77: Healthcare Infrastructure, Singapore, Pharmacists, 2009–2016

Table 78: Healthcare Infrastructure, Singapore, Dentists, 2009–2016

Table 79: Healthcare Infrastructure, Singapore, Healthcare Expenditure as Percentage of GDP (%), 2009–2016

Table 80: Healthcare Infrastructure, Singapore, Public–Private Share of Expenditure (%), 2009–2016

Table 81: Healthcare Infrastructure, Singapore, Major Components of Healthcare Expenditure (%), 2016

Table 82: Healthcare Infrastructure, Singapore, R&D Expenditure ($m), 2009–2016

Table 83: Healthcare Expenditure, Singapore, Major Healthcare Trade Fairs, 2017

List of Figures

Figure 1: Pharmaceutical Market, Singapore, Revenue ($bn), 2009–2021

Figure 2: Country Profile, Singapore, 2017

Figure 3: Pharmaceutical Market, Singapore, Revenue ($m), 2009–2016

Figure ...

Figure 1: Pharmaceutical Market, Singapore, Revenue ($bn), 2009–2021

Figure 2: Country Profile, Singapore, 2017

Figure 3: Pharmaceutical Market, Singapore, Revenue ($m), 2009–2016

Figure 4: Pharmaceutical Market, Singapore, Revenue ($m), 2017–2021

Figure 5: Pharmaceutical Market, Singapore, Exports and Imports ($bn), 2009–2016

Figure 6: Pharmaceutical Market, Singapore, Distribution Channels (%), 2016

Figure 7: Healthcare Market, Singapore, Drivers and Barriers, 2017

Figure 8: Market Access, Singapore, Healthcare Insurance System, 2015

Figure 9: Market Access, Singapore, Healthcare Financing System, 2015

Figure 10: Healthcare Expenditure, Singapore, Out-of-Pocket Expenditure (%), 2009–2016

Figure 11: Market Access, Singapore, Healthcare Consumer Price Index Annual Change (%), 2009–2015

Figure 12: Market Access, Singapore, Organizational Structure of Drug Regulatory Authority, 2016

Figure 13: Market Access, Singapore, Structure of Health Sciences Authority, 2014

Figure 14: Market Access, Singapore, New Drug Application Types, 2014

Figure 15: Market Access, EU, Centralized Procedure for Market Authorization, Pre-submission, 2016

Figure 16: Market Access, EU, Conformity Assessment of Class I Medical Devices, 2016

Figure 17: : Market Access, Singapore, Licensing Process for Import/Export, 2016

Figure 18: Market Access, Singapore, National Patent Approval Process, 2017

Figure 19: Market Access, Singapore, Patent Co-operation Treaty National Phase Entry Process, 2016

Figure 20: Market Access, Singapore, International Patent Approval Process, 2016

Figure 21: Market Access, Singapore, National Trademark Approval Process, 2017

Figure 22: Market Access, Singapore, International Trademark Approval Process, 2017

Figure 23: Market Access, Singapore, Clinical Trial Certificates Issued, 2009–2015

Figure 24: Market Access, Singapore, Clinical Trials by Therapeutic Area (%), 2015

Figure 25: Economic Indicators, Singapore, GDP Per Capita ($), 2009–2016

Figure 26: Economic Indicators, Singapore, GDP per Capita ($), 2017–2021

Figure 27: Economic Indicators, Singapore, GDP Annual Growth (%), 2009–2016

Figure 28: Economic Indicators, Singapore, GDP Annual Growth (%), 2017–2021

Figure 29: Economic Indicators, Singapore, GNI per Capita ($), 2009–2016

Figure 30: Economic Indicators, Singapore, Consumer Price Index, 2009–2016

Figure 31: Economic Indicators, Singapore, Average Consumer Price Index, 2017–2021

Figure 32: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), 2009–2016

Figure 33: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), 2017–2021

Figure 34: Economic Indicators, Singapore, Currency Exchange Rate (SGD/$), 2009–2016

Figure 35: Economic Indicators, Singapore, Foreign Direct Investment ($bn), 2009–2016

Figure 36: Economic Indicators, Singapore, Foreign Exchange Reserves ($bn), 2009–2016

Figure 37: Economic Indicators, Singapore, Imports of Goods and Services ($bn), 2009–2016

Figure 38: Economic Indicators, Singapore, Exports of Goods and Services ($bn), 2009–2016

Figure 39: Economic Indicators, Singapore, Government Structural Balance ($bn), 2009–2016

Figure 40: Economic Indicators, Singapore, Government Net Debt as a Percentage of GDP (%), 2009–2016

Figure 41: Economic Indicators, Singapore, Government Net Debt as a Percentage of GDP (%), 2017–2021

Figure 42: Economic Indicators, Singapore, Value Added by Major Industries ($bn), 2015

Figure 43: Demographics, Singapore, Population (million), 2009–2016

Figure 44: Demographics, Singapore, Population (million), 2017–2021

Figure 45: Demographics, Singapore, Urban–Rural Population Share (%), 2009–2016

Figure 46: Demographics, Singapore, Urban–Rural Population Share (%), 2017–2021

Figure 47: Demographics, Singapore, Population Distribution by Age Group (%), 2009–2016

Figure 48: Demographics, Singapore, Population Distribution by Age Group (%), 2017–2021

Figure 49: Demographics, Singapore, Births (per 1,000 Population), 2009–2016

Figure 50: Demographics, Singapore, Mortality (per 1,000 Population), 2009–2016

Figure 51: Demographics, Singapore, Major Causes of Mortality (%), 2015

Figure 52: Demographics, Singapore, Mortality Rate of Children Under Five (per 1,000 live births), 2009–2016

Figure 53: Demographics, Singapore, Immunization Rate (%), 2009–2016

Figure 54: Demographics, Singapore, Major Causes of Male Mortality (‘000), 2015

Figure 55: Demographics, Singapore, Major Causes of Female Mortality (‘000), 2015

Figure 56: Demographics, Singapore, Gender Ratio (M/F), 2009–2016

Figure 57: Demographics, Singapore, Life Expectancy at Birth (years), 2009–2016

Figure 58: Demographics, Singapore, Life Expectancy at Birth (years), 2017–2021

Figure 59: Demographics, Singapore, Student Enrollment by Level of Education (%), 2015

Figure 60: Demographics, Singapore, Unemployment Rate (%), 2009–2016

Figure 61: Demographics, Singapore, Major Diseases, Disability-Adjusted Life Years by Major Disease (‘000s), 2015

Figure 62: Healthcare Infrastructure, Singapore, Hospitals, 2009–2016

Figure 63: Healthcare Infrastructure, Singapore, Public and Private Hospitals, 2009–2016

Figure 64: Healthcare Infrastructure, Singapore, Hospitals Beds by Sector, 2009–2016

Figure 65: Healthcare Infrastructure, Singapore, Hospitals Beds (per 1,000 population), 2009–2016

Figure 66: Healthcare Infrastructure, Singapore, Doctors (per 1,000 population), 2009–2016

Figure 67: Healthcare Infrastructure, Singapore, PM2.5 (µg per m³), 2009–2016

Figure 68: Healthcare Infrastructure, Singapore, CO2 Emissions (metric tons per capita), 2009–2016

Figure 69: Healthcare Infrastructure, Singapore, Nurses (per 1,000 population), 2009–2016

Figure 70: Healthcare Infrastructure, Singapore, Pharmacists, 2009–2016

Figure 71: Healthcare Infrastructure, Singapore, Dentists, 2009–2016

Figure 72: Healthcare Infrastructure, Singapore, Healthcare Expenditure as Percentage of GDP (%), 2009–2016

Figure 73: Healthcare Infrastructure, Singapore, Public–Private Share of Expenditure (%), 2009–2016

Figure 74: Healthcare Infrastructure, Singapore, Major Components of Healthcare Expenditure (%), 2016

Figure 75: Healthcare Infrastructure, Singapore, R&D Expenditure ($m), 2009–2016

Figure 76: Healthcare Market, Singapore, Opportunities and Challenges, 2016

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports

Many thanks for your quick and well-structured support!

  Multinational Biomedical Technology Company